Michael S. Weiss

Mr. Weiss has served as Chairman of the Board of Directors since May 2015. Mr. Weiss has served in several capacities at Fortress Biotech; since 2014 he has served as Executive Vice Chairman. He also serves as Executive Chairman, President, and Chief Executive Officer of TG Therapeutics, Inc., a company he founded in 2011. From 2002 to 2009, Mr. Weiss was the Chairman and Chief Executive Officer of Keryx Biopharmaceuticals, Inc., where he helped the company acquire and develop its lead drug, Auryxia, as well as execute a strategic alliance for Auryxia with Japan Tobacco, Inc. and Torii Pharmaceutical Co., Ltd. worth more than $100 million. Mr. Weiss began his professional career as a lawyer with Cravath, Swaine & Moore LLP. He earned his J.D. from Columbia Law School and his B.S. in Finance from The University at Albany.